A Breakthrough Therapeutic Platform for Treating Mental Health & Substance Use Disorders at Scale
Personalized Medicine at Scale
NoMore: A Novel Precision Drug Delivery Device
Predictably Human is redefining mental health and addiction care through a patented drug delivery device integrated into a digitally enabled therapeutic platform. With early scientific validation supporting multiple assets across several multibillion-dollar indications, this proprietary technology delivers precision treatment at scale. Predictably Human is uniquely positioned to set a new standard for behavioral health—combining data-driven personalized drug therapy, advanced analytics, and virtual human-centered care.
PROBLEM
Today’s Standard of Care fails Patients, Families and Society
https://www.cdc.gov/mmwr/volumes/73/wr/mm7325a1.htm#:~:text=Results,medications%20for%20OUD%20(Figure).
https://www.tfah.org/report-details/pain-in-the-nation-2024/
Pharmacological and Psychological are rarely combined
SOLUTION
NoMore: A patented smart drug delivery device that aerosolizes medications and intelligently controls dosing, and is combined with persona-based digital thereupetic
PLATFORM
Combines three technologies into one integrated platform
Predictably Human created a closed-loop, personalized and precision medication delivery Platform with patented DuoTOME™ Technology for the treatment of addictions and mental illness.
Precision Drug Delivery Device
DuoTOME™ powered, configurable, on-demand microfluidics & aerosolization device for safe, adaptive drug delivery
Cloud-Based Data and Analytics
AI & continuous monitoring with alerts for patients & clinicians with individual & population-based learning
Mobile Companion App
Behavioral support, digital controls, dynamic inputs, continuous monitoring, and adaptation
IMPACT
Benefits the Entire Ecosystem
Benefits drive adoption and improved outcomes that fuel reduced costs and contribute to value based care. From payment to distribution, our Platform scales within today’s complex healthcare enviroment.
PROVIDERS
- Better outcomes
- Improved patient engagement
- Better patient monitoring
- Physician alerts for early intervention
- Risk sharing and value- based opportunities
- API’s for standard EMRs & Telehealth assess
PAYERS
- Reduction in ER visits
- Value-based reimbursement opportunities
- API integration with care management systems
- Lower overall cost of care
- Standard drug formularly pricing
PHARMA
- Improved efficacy and lower toxicity for drugs in development
- Extended exclusivity periods for older drugs
- Better patient engagement and adherence
- Lower abuse, unintended use and dependence
OPERATING MODEL
Defined Business Process Brings Multiple Indications to Market
Product development process designed to generate IND and clinical data sufficient to seek a commercialization partner with $15 million investment per indication – each drug can generate $250+ million in revenue
MARKET OPPORTUNITY
US TAM for current pipeline exceeds $50B for several disorders that lack effective, safe and/or scalable therapies
https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html
https://www.cdc.gov/nchs/products/databriefs/db524.htm
https://pubmed.ncbi.nlm.nih.gov/30554562/#:~:text=Results%3A%20A%20total%20of%2030.6,highest%20prescribed%20use%20(12.9%25).
https://www.cdc.gov/mmwr/volumes/73/wr/mm7325a1.htm#:~:text=Results,medications%20for%20OUD%20(Figure).
https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm
https://www.cdc.gov/nchs/fastats/inpatient-surgery.htm/?utm_source=chatgpt.com
https://www.prnewswire.com/news-releases/united-states-outpatient-surgical-procedures-market-2019-2023-rising-number-of-outpatient-surgical-procedures-in-ascs-hopds-and-physicians-office-300783771.html
VALIDATION
$2.6 Million Grant Award
Phase 1: Advance benchtop prototype and prove the technology supports the science (successfully completed).
Phase 2: Prove safety and achieve FDA IND clearance to study efficacy (awarded May 2025).
Repeat (apply for new grants):
Opioid Use Disorder & Benzodiazepine Dependence (In Process).
Strategic Partnership & Equity Investor
In early 2025, we integrated Aerogen’s mesh technology into a prototype and proved our Device supports dynamic aerosol adaptation, the key to improving therapeutic outcomes.
Personalized Adaptation
For each dose, we can adjust:
- Volume
- Concentration
- Deposition targets
- Daily doses
TEAM
World-class Healthcare and Technology Leadership
CLINICAL, SCIENTIFIC AND TECHNOLOGY LEADERS & ADVISORS
Thought Leaders and Practioners Across Mental Health and Substance Use Disorders
The future of mental health and addiction care is here — and you can help bring it to life.
Predictably Human is redefining how we treat complex disorders with a breakthrough smart drug delivery platform that adapts to each patient. We’ve got momentum, visionary partners, and cutting-edge tech — now we’re inviting a select few to join us in this final stretch. This is your chance to get in early and be part of something truly transformative.
